Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy.

Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP.

Amyloid. 2012 Jun;19 Suppl 1:43-4. doi: 10.3109/13506129.2012.673140. Epub 2012 Apr 12.

PMID:
22494066
2.

Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.

Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, Kim TW, Jesse Kwoh T, Matson J, Norris D, Yu R, Watt A, Monia BP.

Amyloid. 2016 Sep;23(3):148-157. Epub 2016 Jun 29.

PMID:
27355239
3.

Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment.

Benson MD, Smith RA, Hung G, Kluve-Beckerman B, Showalter AD, Sloop KW, Monia BP.

Amyloid. 2010 Jun;17(2):43-9. doi: 10.3109/13506129.2010.483121.

PMID:
20462362
4.

[Gene therapy in familial amyloidotic polyneuropathy by single-stranded oligonucleotides (SSOs)].

Nakamura M, Ando Y.

Rinsho Byori. 2004 Oct;52(10):804-12. Japanese.

PMID:
15624495
5.

Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.

João Saraiva M, Mendes Sousa M, Cardoso I, Fernandes R.

J Mol Neurosci. 2004;23(1-2):35-40. Review.

PMID:
15126690
6.

Recent progress in the understanding and treatment of transthyretin amyloidosis.

Sekijima Y.

J Clin Pharm Ther. 2014 Jun;39(3):225-33. doi: 10.1111/jcpt.12145. Review.

PMID:
24749898
7.

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides.

Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW.

Muscle Nerve. 2006 May;33(5):609-18.

PMID:
16421881
8.

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.

Niemietz C, Chandhok G, Schmidt H.

Molecules. 2015 Sep 30;20(10):17944-75. doi: 10.3390/molecules201017944. Review.

9.

[Pathogenesis and therapy for transthyretin related amyloidosis].

Ando Y, Jono H.

Rinsho Byori. 2008 Feb;56(2):114-20. Review. Japanese.

PMID:
18402051
10.

Familial amyloid polyneuropathy.

Barreiros AP, Galle PR, Otto G.

Dig Dis. 2013;31(1):170-4. doi: 10.1159/000347214. Epub 2013 Jun 17. Review.

PMID:
23797140
11.

Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology.

Sekijima Y, Hammarström P, Matsumura M, Shimizu Y, Iwata M, Tokuda T, Ikeda S, Kelly JW.

Lab Invest. 2003 Mar;83(3):409-17.

PMID:
12649341
12.

[Familial amyloid polyneuropathy].

Yamashita T, Ando Y, Uchino M.

Brain Nerve. 2011 Jun;63(6):583-95. Review. Japanese.

PMID:
21613661
13.

Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant.

Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, Pflugfelder PW, Fox Z, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD.

Eur Heart J. 2012 May;33(9):1120-7. doi: 10.1093/eurheartj/ehr383. Epub 2011 Oct 11.

PMID:
21992998
14.

Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity.

Ikeda S, Nakazato M, Ando Y, Sobue G.

Neurology. 2002 Apr 9;58(7):1001-7. Review.

PMID:
11940682
15.
16.

Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy.

Palha JA, Moreira P, Olofsson A, Lundgren E, Saraiva MJ.

J Mol Med (Berl). 2001;78(12):703-7.

PMID:
11434723
17.

Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis.

Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson DR, Tagoe C, Gallo G, Buxbaum J.

Lab Invest. 2001 Mar;81(3):385-96. Erratum in: Lab Invest 2002 Mar;82(3):241.

PMID:
11310831
18.

Liver transplantation in transthyretin-related familial amyloid polyneuropathy.

Stangou AJ, Hawkins PN.

Curr Opin Neurol. 2004 Oct;17(5):615-20. Review.

PMID:
15367866
19.

Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.

Palhano FL, Leme LP, Busnardo RG, Foguel D.

J Biol Chem. 2009 Jan 16;284(3):1443-53. doi: 10.1074/jbc.M807100200. Epub 2008 Nov 4.

20.

Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.

Wei L, Kawano H, Fu X, Cui D, Ito S, Yamamura K, Ishihara T, Tokuda T, Higuchi K, Maeda S.

Amyloid. 2004 Jun;11(2):113-20.

PMID:
15478467

Supplemental Content

Support Center